Ricardo Gómez García-rekin lankidetzan egindako argitalpenak (17)

2013

  1. p.D1690N Nav1.5 rescues p.G1748D mutation gating defects in a compound heterozygous Brugada syndrome patient

    Heart Rhythm, Vol. 10, Núm. 2, pp. 264-272

2008

  1. Effects of MiRP1 and DPP6 β-subunits on the blockade induced by flecainide of K V4.3/KChIP2 channels

    British Journal of Pharmacology, Vol. 154, Núm. 4, pp. 774-786

  2. Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1)

    Cardiovascular Research, Vol. 80, Núm. 3, pp. 375-384

  3. The HERACLES cardiovascular network

    Revista Espanola de Cardiologia, Vol. 61, Núm. 1, pp. 66-75

2007

  1. Effects of atorvastatin and simvastatin on atrial plateau currents

    Journal of Molecular and Cellular Cardiology, Vol. 42, Núm. 5, pp. 931-945

  2. Genetically engineered mice as a model for studying cardiac arrhythmias

    Frontiers in Bioscience, Vol. 12, Núm. 1, pp. 22-38

  3. Ivabradina, un bloqueador selectivo de la corriente If. Aspectos farmacológicos y tolerabilidad

    Revista Espanola de Cardiologia Suplementos, Vol. 7, Núm. D

  4. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy

    Pharmacology and Therapeutics, Vol. 114, Núm. 1, pp. 107-126

2006

  1. Association of 14-3-3 proteins to β1-adrenergic receptors modulates Kv11.1 K+ channel activity in recombinant systems

    Molecular Biology of the Cell, Vol. 17, Núm. 11, pp. 4666-4674

  2. Características farmacológicas de los ARA-II. ¿Son todos iguales?

    Revista Espanola de Cardiologia Suplementos, Vol. 6, Núm. C

  3. Effects of nitric oxide on cardiac function

    Revista Espanola de Cardiologia Suplementos, Vol. 6, Núm. A

  4. Mecanismo de acción de la eplerenona

    Revista Espanola de Cardiologia Suplementos, Vol. 6, Núm. B

  5. Nitric oxide blocks hKv1.5 channels by S-nitrosylation and by a cyclic GMP-dependent mechanism

    Cardiovascular Research, Vol. 72, Núm. 1, pp. 80-89

2005

  1. Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization

    Trends in Pharmacological Sciences, Vol. 26, Núm. 3, pp. 155-161

  2. Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels

    British Journal of Pharmacology, Vol. 146, Núm. 1, pp. 146-161

2004

  1. Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations

    Cardiovascular Research, Vol. 64, Núm. 3, pp. 457-466

  2. Interaction of angiotensin II with the angiotensin type 2 receptor inhibits the cardiac transient outward potassium current

    Cardiovascular Research, Vol. 62, Núm. 1, pp. 86-95